New drug combo tested for Tough-to-Treat head and neck cancers
NCT ID NCT06332092
Summary
This study is testing a new drug, FID-007, given alongside an existing cancer drug called cetuximab. It aims to see if this combination can help control advanced head and neck cancer that has come back or spread after prior treatment. Researchers will compare two different dosing schedules of FID-007 to find the most effective and safest approach for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46804, United States
-
Highlands Oncology - North Hills
Fayetteville, Arkansas, 72703, United States
-
Moffitt Cancer Center Magnolia Campus
Tampa, Florida, 33612, United States
-
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Texas Oncology - Northeast Texas Cancer & Research Institute
Tyler, Texas, 75702, United States
-
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.